Resistance to third generation cephalosporins in Sfax hospitals, Tunisia (1999-2005);Étude de la résistance des entérobactéries aux céphalosporines de troisième génération dans les hôpitaux de Sfax, Tunisie (1999-2005)

Medecine et Maladies Infectieuses

Volumn 38, Issue 6, 2008, Pages 293-298

  Mkaouar, D ^a   Mahjoubi, F ^a   Mezghani, S ^a   Znazen, A ^a   Ktari, S ^a   Hammami, A ^a  

^a HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Enterobacteria; Resistance; Third generation cephalosporins

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COMPUTER PROGRAM; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; NONHUMAN; PREVALENCE; PROTEUS; SALMONELLA; TEACHING HOSPITAL; TUNISIA; WARD; DRUG EFFECT; ENTEROBACTER; ENTEROBACTER INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RETROSPECTIVE STUDY; SUPPURATION;

CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; SUPPURATION; TUNISIA;

EID: 44649177248     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2007.11.017     Document Type: Article

References (23)

1. Amazian K., Fendri C., Missoum M.F.K., Bouzouaia N., Rahal K., Savey A., et al. Multicenter pilot survey of resistant bacteria in the Mediterranean area. Eur J Clin Microbiol Infect Dis 25 (2006) 340-343
2. Boutiba I., Ghozzi R., Ben Abdallah H., Mamlouk K., Kamoun A., and Ben Redjeb S. Evolution of acquired resistance to third generation Cephalosporins in Enterobacteriaceae in a Tunisian Hospital 1993-2001. Clin Microbiol Infect 10 7 (2004) 657-678
3. Chaudhary U., and Aggarwal R. Extended spectrum β-lactamases: an emerging threat to clinical Therapeutics. Indian J Med Microbiol 22 2 (2004) 75-80
4. Christel H., Arlet G., and Goutier V. β-lactamases of kluyvera ascorbata: probable progenitors of some plasmid encoded CTX - M Types. Antimicrob Agents Chemother (2002) 3045-3049
5. Comité de l'antibiogramme de la société Française de microbiologie. Communiqué 2006. http://www.SFM.assa.fr.
6. El Kholy A., Baseem H., Hall G.S., Procop G.W., and Longworth D.L. Antimicrobial resistance in Cairo, Egypt 1999-2000: a Survey of five hospitals. J Antimicrob Chemother 51 (2003) 625-630
7. Gniadkowski M. Evolution and epidemiology of Extended Spectrum β-lactamases and ESBL- producing microorganisms. Clin Microbiol infect 7 11 (2001) 597-608
8. Hammami A., Arlet G., Ben Redjeb S., Grimont F., Ben Hassen A., Rekik A., et al. Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in Tunisia caused by multiply drug resistant Salmonella Wien producing SHV-2 β-lactamase. Euro J Clin Microbiol Infect Dis 10 8 (1991) 641-646
9. Hirakata Y., Matsuda J., Miyazaki Y., Kamihira S., Kawakami S., Miyazawa Y., et al. Regional variation in the prevalence of extended - spectrum (-lactamase - producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 52 (2005) 323-329
10. Jones R.N., Pfaller M.A., and and the MYSTIC Study Group (Europe). Antimicrobial activity against strains of E.coli and Klebsiella spp. with resistance phenotypes consistent with an extended Spectrum β-lactamase in Europe. Clin Microbiol Infect 9 (2003) 708-712
11. Karlowsky J.A., Jones M.E., Thornsberry C., Friedland I.R., and Sahm D.F. Trends in Antimicrobial susceptibilities among Enterobacteriaceae isolated from Hospitalized Patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 47 5 (2003) 1672-1682
12. Ktari S., Arlet G., Mnif B., Gautier V., Mahjoubi F.B., Jmeaa M., et al. Emergence of Multidug-Resistant Klebsiella pneumoniae Isolates Producing VIM-4 Metallo- β-lactamase, CTX-M-15 Extended spectrum β-lactamase and CMY-4 AmpC β-lactamase in a Tunisian university hospital. Antimicrob Agents Chemother 50 12 (2006) 4198-4201
13. Ktari S., Mahjoubi F., Jaoua S., Karray A., Marty N., Ben Redjeb S., et al. Application de marqueurs génotypiques dans l'investigation de deux épidémies d'infections nosocomiales à Salmonella Livingstone dans le CHU de Sfax, Tunisie. Pathol Biol 54 (2006) 331-336
14. Mahjoubi F., Bernier M., Arlet G., et al. Identification of Plasmid - encoded cephalosporinase ACC - 1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella spp) isolated from a Tunisian hospital (Sfax 1997-2000). Pathol Biol 50 (2002) 7-11
15. Masterton R.G., and Turner P.J. Trends in antimicrobial Susceptibility in UK centers: the MYSTIC program (1997-2002). Int J Antimicrob Agents 27 (2006) 69-72
16. Navon-Venezia S., Hammer-Munz O., Schwartz D., Turner D., Kuzmenko B., and Carmeli Y. Occurrence and Phenotypic characteristics of Extended Spectrum β-lactamases among Members of the family Enterobacteriaceae at the Tel-Aviv Medical center (Israel) and Evaluation of Diagnostic Tests. J Clin Microbiol 41 1 (2003) 155-158
17. Quinteros M., Radice M., Gardella N., Rodriguez M.M., Costa N., Korbenfeld D., et al. Extended Spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob Agents Chemother 47 9 (2003) 2864-2867
18. Mathai D., Rhomberg P.R., Biedenbach D.J., Jones R.N., and The India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad Spectrum β-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 44 (2002) 367-377
19. Turner P.J. Extended spectrum β-lactamases. Clin infect dis 41 (2005) 5273-5275
20. Turner P.J. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centres: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis 51 (2005) 281-289
21. Verdet C., Arlet G., Ben Redjeb S., Ben Hassen A., Laguange Ph., and Philippon A. Characterization of CMY- 4 in AmpC type plasmid mediated β-lactamase in a Tunisian clinical isolate of Proteus mirabilis. FEMS Microbiol lett 169 (1998) 235-240
22. Von Baum H., and Marre R. Antimicrobial resistance of Escherichia coli and Therapeutic implications. Int J Med Microbiol 295 (2005) 503-511
23. Winokur I.L., Canton K., Casellas J.M., and Legakis N. Variations in the prevalence of strains expressing an extended spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin Infect Dis 32 Suppl. 2 (2001) S49-S103